JAMA:危重患者插管不良事件发生率研究

2021-03-24 MedSci原创 MedSci原创

危重病人插管后不良事件率近50%,最主要因素是心血管指标不稳定

气管插管是一种高风险操作,紧急插管通常在危重病患者中进行,但对插管导致的不良事件的了解却相对较少。与手术插管患者相比,危重症患者因潜在的休克、呼吸衰竭和代谢性酸中毒风险导致插管相关并发症风险增加。小规模研究中,在接受气管插管的危重病人中,28%可能会出现呼吸抑制并发症,如严重低氧血症或血流动力学不稳定,2.7%出现心脏骤停。
近日研究人员评估了危重病人插管期间不良事件的发生率和性质
INTUBE研究旨在了解气道管理对危重病人的影响和最佳做法,研究时间为2018年10月1日到2019年7月31日,样本来自五大洲29个国家的197个ICU中心。研究的主要结果是主要不良插管事件的发生率,定义为插管开始后30分钟内发生以下事件:血管指标不稳定(包括:心脏收缩压<65 mm Hg,持续30分钟以上的收缩压<90 mm Hg,使用血管升压类药物或剂量>15ml/kg),严重低氧血症(外周血氧饱和度<80%)或心脏骤停。次要结果为重症监护病房死亡率。
 
2964名患者参与研究,平均年龄63岁,62.6%为男性。52.3%的患者因出现呼吸衰竭而插管, 30.5%因神经损伤插管,9.4%因心血管指标不稳定而插管。研究中,45.2%的患者至少经历过一次主要的不良插管事件,主要原因是心血管指标不稳定,其中42.6%的紧急插管患者出现心血管指标不稳定。其次是严重低氧血症(9.3%)和心脏骤停(3.1%)。ICU总死亡率为32.8%。
研究发现,危重病人插管后不良事件率近50%,最常见的是心血管指标不稳定
 
原始出处
 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1826678, encodeId=f0e718266e899, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon May 31 21:14:43 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961902, encodeId=e767961902bf, content=<a href='/topic/show?id=08af1024310' target=_blank style='color:#2F92EE;'>#JAMA#</a>点击进入话题查看更多相关文章 或评论时插入话题加入讨论, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10243, encryptionId=08af1024310, topicName=JAMA)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:28:11 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955635, encodeId=321095563589, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b873030482, createdName=jywsoar, createdTime=Sat Apr 10 09:19:30 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950921, encodeId=b60b9509213b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80c75472899, createdName=ms3000001498300824, createdTime=Thu Mar 25 08:52:19 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036542, encodeId=4a521036542b5, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Mar 25 00:14:43 CST 2021, time=2021-03-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1826678, encodeId=f0e718266e899, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon May 31 21:14:43 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961902, encodeId=e767961902bf, content=<a href='/topic/show?id=08af1024310' target=_blank style='color:#2F92EE;'>#JAMA#</a>点击进入话题查看更多相关文章 或评论时插入话题加入讨论, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10243, encryptionId=08af1024310, topicName=JAMA)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:28:11 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955635, encodeId=321095563589, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b873030482, createdName=jywsoar, createdTime=Sat Apr 10 09:19:30 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950921, encodeId=b60b9509213b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80c75472899, createdName=ms3000001498300824, createdTime=Thu Mar 25 08:52:19 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036542, encodeId=4a521036542b5, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Mar 25 00:14:43 CST 2021, time=2021-03-25, status=1, ipAttribution=)]
    2021-04-30 MedSciZeng

    #JAMA#点击进入话题查看更多相关文章 或评论时插入话题加入讨论

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1826678, encodeId=f0e718266e899, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon May 31 21:14:43 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961902, encodeId=e767961902bf, content=<a href='/topic/show?id=08af1024310' target=_blank style='color:#2F92EE;'>#JAMA#</a>点击进入话题查看更多相关文章 或评论时插入话题加入讨论, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10243, encryptionId=08af1024310, topicName=JAMA)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:28:11 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955635, encodeId=321095563589, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b873030482, createdName=jywsoar, createdTime=Sat Apr 10 09:19:30 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950921, encodeId=b60b9509213b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80c75472899, createdName=ms3000001498300824, createdTime=Thu Mar 25 08:52:19 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036542, encodeId=4a521036542b5, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Mar 25 00:14:43 CST 2021, time=2021-03-25, status=1, ipAttribution=)]
    2021-04-10 jywsoar

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1826678, encodeId=f0e718266e899, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon May 31 21:14:43 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961902, encodeId=e767961902bf, content=<a href='/topic/show?id=08af1024310' target=_blank style='color:#2F92EE;'>#JAMA#</a>点击进入话题查看更多相关文章 或评论时插入话题加入讨论, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10243, encryptionId=08af1024310, topicName=JAMA)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:28:11 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955635, encodeId=321095563589, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b873030482, createdName=jywsoar, createdTime=Sat Apr 10 09:19:30 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950921, encodeId=b60b9509213b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80c75472899, createdName=ms3000001498300824, createdTime=Thu Mar 25 08:52:19 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036542, encodeId=4a521036542b5, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Mar 25 00:14:43 CST 2021, time=2021-03-25, status=1, ipAttribution=)]
    2021-03-25 ms3000001498300824

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1826678, encodeId=f0e718266e899, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon May 31 21:14:43 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961902, encodeId=e767961902bf, content=<a href='/topic/show?id=08af1024310' target=_blank style='color:#2F92EE;'>#JAMA#</a>点击进入话题查看更多相关文章 或评论时插入话题加入讨论, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10243, encryptionId=08af1024310, topicName=JAMA)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:28:11 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955635, encodeId=321095563589, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b873030482, createdName=jywsoar, createdTime=Sat Apr 10 09:19:30 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950921, encodeId=b60b9509213b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80c75472899, createdName=ms3000001498300824, createdTime=Thu Mar 25 08:52:19 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036542, encodeId=4a521036542b5, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Mar 25 00:14:43 CST 2021, time=2021-03-25, status=1, ipAttribution=)]
    2021-03-25 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

相关资讯

NEJM:动脉氧分压治疗目标对急性低氧性呼吸衰竭患者死亡风险的影响

对于因急性低氧性呼吸衰竭接受ICU治疗的患者,降低动脉氧分压治疗目标至60mmHG不能降低患者死亡风险

JAMA:提高预防性抗凝治疗药物剂量对ICU新冠肺炎患者预后的影响

,接受ICU治疗的COVID-19患者中,与标准预防性抗凝治疗相比,提高依诺肝素预防性抗凝治疗剂量,在降低患者静脉或动脉血栓、体外膜氧合或30天内死亡风险方面无优势

胆小勿入:你们的亲人送入ICU,都会受到哪些“酷刑”

一个35岁的独肾患者,发生了肾结石、感染、感染性休克,病情危重,已经昏迷,病人老婆签字送入ICU,经过2个星期的处理后,患者重获新生,不发热了,感染指标下降了,尿量开始增多了,休克逆转了,人也清醒了,

JAMA:ICU患者有创机械通气中止及对预后的影响

各国ICU中断有创机械通气的标准各不相同,但直接拔管患者的预后最佳

被错开10倍剂量,广西一男子用药后进ICU并丧失性功能

近日,据多家媒体报道,今年4月,50岁的患者孙某因皮肤瘙痒到广西医科大学第二附属医院皮肤科就诊,医生为其开具了多种药物,其中一种为雷公藤多苷片,共9瓶,要求“每日服用三次,每次20片,饭后服”。

ICU床位数四年增幅达16.4%,重症医学将迎来信息化大发展?

每当遇到重大公共卫生事件时,重症医学科便会引起社会的广泛关注和重视。